reports
Kuros Biosciences AG: 1 director
A director at Kuros Biosciences AG sold 225,000 shares at 20.900CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Kuros Biosciences Expands into Extremities Markets
Kuros Biosciences AG / Key word(s): Miscellaneous/Personnel Kuros Biosciences Expands into Extremities Markets 19.11.2024 / 07:00 CET/CEST Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration beyond the spine market Strategic expansion opens new addressable market opportunity estimated at $1 billion Formation of a dedicated Surgeon Advisory Board to shape clinical and commercial strategies for MagnetOsTM in extremities markets Schlieren (Zurich), Switzerland, November 19, 2024 – Kuros Bioscie...
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA...
Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, multi-center, randomized, intra-patient controlled clinical study in Spine1. Published clinica...
Annual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2023 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the Executive Committee, voted i...
Kuros Biosciences to Report Full Year Financial Results for 2023 and P...
Kuros Biosciences AG / Key word(s): Annual Results Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST - Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024. Following the announcement, the company w...
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, February 1, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024. At the conference, management will discuss its novel MagnetOs portfolio of products and its application to spinal fusion. Presentation details are as follows: Pres...
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules...
Kuros Biosciences AG / Key word(s): Regulatory Admission/Market Launch Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand 31.01.2024 / 07:00 CET/CEST MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs Granules and MagnetOs Putty in New Zealand via an exclusive distribution agreement with Vortek Spine Limited, a high-te...
Kuros Biosciences Announces Three Advancements Related to its MagnetOs...
Kuros Biosciences AG / Key word(s): Study results/Preliminary Results Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA 04.01.2024 / 07:00 CET/CEST New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the challenging posterior spinal fusion approach, demonstrates a fusion rate of 78% versus 45% after one year In the difficult-to-treat patient population of smokers, MagnetOs demo...
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interb...
Kuros Biosciences AG / Key word(s): Regulatory Approval Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages 28.11.2023 / 18:00 CET/CEST MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody use MagnetOs can now be used on-label in any interbody cage cleared for use with a bone void filler The exceptional handling properties of MagnetOs Flex Matrix are uniquely applicable to interbody applications Schlieren (Zurich), Switzerland, November 28, 2023 – Kuros Biosciences (“Kur...
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH...
Kuros Biosciences AG / Key word(s): Study results Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial 13.07.2023 / 19:29 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to address $2.2B market opportunity Schlieren (Zurich), Switzerland, July 13, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the STRUCTURE trial, which is investigating the ...
Kuros Biosciences Announces Publication of Supportive Osteoimmunology ...
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft 21.02.2023 / 07:00 CET/CEST Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds to body of evidence for MagnetOs, using data from human and animal models Schlieren (Zurich), Switzerland, 21 February, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announced the publication of key scientific data on...
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 ...
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH 23.11.2022 / 07:00 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial Enrollment of additional 20 patients for second non-randomized stage underway Potential to address a major commercial opportunity Schlieren (Zurich), Switzerland, 23 November, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next g...
Kuros Biosciences completes enrolment in Level 1 clinical study of Mag...
Kuros Biosciences AG / Key word(s): Study Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules 02.11.2022 / 07:00 CET/CEST Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical study compares MagnetOs Granules to local autograft in patients undergoing posterolateral lumbar fusion First of five randomized controlled Level 1 trials for MagnetOs to complete enrolment Schlieren (Zurich), Switzerland, November 2, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in n...
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Fle...
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week 19.10.2022 / 07:00 CET/CEST MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product Rounds out MagnetOs portfolio to provide more solutions for surgeons Schlieren (Zurich), Switzerland, 19 October 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announces that it has received the 2022 Spine Technology Award from the widely-read ind...
Kuros Biosciences to present positive clinical data for MagnetOs at NA...
Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands perioperative options for surgeons Schlieren (Zurich), Switzerland, 11 October, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next gener...
Kuros Biosciences to present positive clinical data for MagnetOs at NA...
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands perioperative options for surgeons Schlieren (Zurich), Switzerland, 11 October, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will present compelling clinical data on...
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key...
Kuros Biosciences AG / Key word(s): Corporate Action Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones 23.08.2022 / 07:00 CET/CEST Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with MagnetOs worldwide Schlieren (Zurich), Switzerland, August 23, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs bone graft has successfully achieved three key cl...
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmace...
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REG...
Kuros Biosciences announces favorable preliminary results of MagnetOs ...
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial 31.05.2022 / 07:00 Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs Data will support product approvals at hospitals and within hospital systems Schlieren (Zurich), Switzerland, May 31, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft t...
Kuros Biosciences announces commercial launch of MagnetOs Easypack P...
Kuros Biosciences AG / Key word(s): Product Launch Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S. 18.05.2022 / 07:00 Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Schlieren (Zurich), Switzerland, May 18, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the commercial launch of MagnetOs Easypack Putty in the U.S., at the 22nd Annual Meeting of the International Society for the Advance...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.